Skip to main content

Thyroid Neuroendocrine Neoplasms

  • Chapter
  • First Online:
The Spectrum of Neuroendocrine Neoplasia

Abstract

The thyroid is the location of neuroendocrine C cells that produce calcitonin. The most common thyroid neuroendocrine neoplasm is medullary thyroid carcinoma (MTC) that is composed of C cells. Rare other thyroid neuroendocrine neoplasms include mixed neuroendocrine and non-neuroendocrine neoplasms (MiNENs) that represent a composite MTC and thyroid follicular neoplasm, usually papillary thyroid carcinoma, as well as occasional paragangliomas, intrathyroidal parathyroid tumors, NENs originating from intrathyroidal thymic remnants and metastatic neuroendocrine neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hurthle K. Beitrage zur Kenntiss der Secretionsvorgangs in der Schilddruse. Arch Gesamte Physiol. 1894;56:1–44.

    Article  Google Scholar 

  2. Warren S, Meissner WA. Tumors of the thyroid gland. Atlas of tumor pathology, series 1, fascicle 14. Washington, D.C.: Armed Forces Institute of Pathology; 1953.

    Google Scholar 

  3. Horn RC. Carcinoma of the thyroid. Description of a distinctive morphologic variant and report of 7 cases. Cancer. 1951;4:697–707.

    Article  Google Scholar 

  4. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19(1):152–61.

    Article  CAS  PubMed  Google Scholar 

  5. Copp DH, Cheney B. Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood. Nature. 1962;193:381–2.

    Article  CAS  PubMed  Google Scholar 

  6. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol. 1966;19:114–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Le DN, Fontaine J, Le LC. New studies on the neural crest origin of the avian ultimobranchial glandular cells--interspecific combinations and cytochemical characterization of C cells based on the uptake of biogenic amine precursors. Histochemistry. 1974;38(4):297–305.

    Article  Google Scholar 

  8. Johansson E, Andersson L, Ornros J, et al. Revising the embryonic origin of thyroid C cells in mice and humans. Development. 2015;142(20):3519–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Kameda Y. Cellular and molecular events on the development of mammalian thyroid C cells. Dev Dyn. 2016;245(3):323–41.

    Article  CAS  PubMed  Google Scholar 

  10. Williams ED. A review of 17 cases of carcinoma of the thyroid and phaeochromocytoma. J Clin Pathol. 1965;18:288–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mulligan LM, Kwok JBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.

    Article  CAS  PubMed  Google Scholar 

  12. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. Atlas of tumor pathology, third series, fascicle 5. Armed Forces Institute of Pathology: Washington, D.C; 1992.

    Google Scholar 

  14. Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin N Am. 2008;37(2):481–96.

    Article  CAS  Google Scholar 

  15. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of Tumours of endocrine organs. Lyons: IARC Press; 2004.

    Google Scholar 

  16. Baloch ZW, LiVolsi VA. C-cells and their associated lesions and conditions: a pathologists perspective. Turk Patoloji Derg. 2015;31(Suppl 1):60–79.

    PubMed  Google Scholar 

  17. Trimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2015;82(2):280–5.

    Article  Google Scholar 

  18. Essig GF Jr, Porter K, Schneider D, et al. Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Endocr Pract. 2013;19(6):920–7.

    Article  PubMed  Google Scholar 

  19. Driman D, Murray D, Kovacs K, Stefaneanu L, Higgins HP. Encapsulated medullary carcinoma of the thyroid. A morphologic study including immunohistochemistry, electron microscopy flow cytometry, and in situ hybridization. Am J Surg Pathol. 1991;15:1089–95.

    Article  CAS  PubMed  Google Scholar 

  20. Mete O, Essa A, Bramdev A, Govender N, Chetty R. MEN2 syndrome-related medullary thyroid carcinoma with focal tyrosine hydroxylase expression: does it represent a hybrid cellular phenotype or functional state of tumor cells? Endocr Pathol. 2017;28(4):362–6.

    Article  CAS  PubMed  Google Scholar 

  21. Harach HR, Williams ED. Glandular (tubular and follicular) variants of medullary carcinoma of the thyroid. Histopathology. 1983;7:83–97.

    Article  CAS  PubMed  Google Scholar 

  22. Kawanishi N, Norimatsu Y, Ohsaki H, et al. Diagnosis of pseudopapillary variant of medullary thyroid carcinoma by fine-needle aspiration cytology. Diagn Cytopathol. 2014;42(9):823–6.

    Article  PubMed  Google Scholar 

  23. Ozkara SK, Gurbuz Y, Muezzinoglu B, Yumbal Z. Encapsulated cystic papillary variant of medullary carcinoma of thyroid gland. Endocr Pathol. 2002;13(2):167–71.

    Article  PubMed  Google Scholar 

  24. Hyrcza MD, Winer D, Mete O. Images in endocrine pathology: papillary variant of medullary thyroid carcinoma with cystic change. Endocr Pathol. 2015;26(1):87–9.

    Article  PubMed  Google Scholar 

  25. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. 2004;57(3):225–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol. 2010;21(1):16–24.

    Article  PubMed  Google Scholar 

  27. Santosh KV, Raychaudhuri S, Subramanya H, Naveen Kumar BJ. Cytology of hyalinising trabecular adenoma-like variant of medullary thyroid carcinoma. J Cancer Res Ther. 2011;7(2):189–91.

    Article  CAS  PubMed  Google Scholar 

  28. Bhat V, Shariff S, Reddy RA. Extramedullary plasmacytoma of thyroid – a mimicker of medullary carcinoma at fine needle aspiration cytology: a case report. J Cytol. 2014;31(1):53–6.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Rekhi B, Kane SV, D’Cruz A. Cytomorphology of anaplastic giant cell type of medullary thyroid carcinoma–a diagnostic dilemma in an elderly female: a case report. Diagn Cytopathol. 2008;36(2):136–8.

    Article  PubMed  Google Scholar 

  30. Ikeda T, Satoh M, Azuma K, Sawada N, Mori M. Medullary thyroid carcinoma with a paraganglioma-like pattern and melanin production: a case report with ultrastructural and immunohistochemical studies. Arch Pathol Lab Med. 1998;122(6):555–8.

    CAS  PubMed  Google Scholar 

  31. Laforga JB, Aranda FI. Pseudoangiosarcomatous features in medullary thyroid carcinoma spindle-cell variant. Report of a case studied by FNA and immunohistochemistry. Diagn Cytopathol. 2007;35(7):424–8.

    Article  PubMed  Google Scholar 

  32. Valenta LJ, Michel-Bechet M, Mattson JC, Singer FR. Microfollicular thyroid carcinoma with amyloid rich stroma, resembling the medullary carcinoma of the thyroid (MCT). Cancer. 1977;39:1573–86.

    Article  CAS  PubMed  Google Scholar 

  33. Polliack A, Freund U. Mixed papillary and follicular carcinoma of the thyroid gland with stromal amyloid. Am J Clin Pathol. 1970;53:592–5.

    Article  CAS  PubMed  Google Scholar 

  34. Di CV, Garzi A, Petruzziello F, et al. Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature. BMC Surg. 2013;13 Suppl 2:S43.

    Google Scholar 

  35. Nobuoka Y, Hirokawa M, Kuma S, et al. Cytologic findings and differential diagnoses of primary thyroid MALT lymphoma with striking plasma cell differentiation and amyloid deposition. Diagn Cytopathol. 2014;42(1):73–7.

    Article  PubMed  Google Scholar 

  36. Wang AR, Baloch ZW, Montone KT. Amyloid goiter in a patient with progressive thyromegaly. Endocr Pathol. 2016;27(1):76–8.

    Article  PubMed  Google Scholar 

  37. Asa SL, Kovacs K, Killinger DW, Marcon N, Platts M. Pancreatic islet cell carcinoma producing gastrin, ACTH, α-endorphin, somatostatin and calcitonin. Am J Gastroenterol. 1980;74:30–5.

    CAS  PubMed  Google Scholar 

  38. Nozieres C, Chardon L, Goichot B, et al. Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up. Eur J Endocrinol. 2016;174(3):335–41.

    Article  CAS  PubMed  Google Scholar 

  39. Uccella S, Blank A, Maragliano R, Sessa F, Perren A, La RS. Calcitonin-producing neuroendocrine neoplasms of the pancreas: clinicopathological study of 25 cases and review of the literature. Endocr Pathol. 2017;28(4):351–61.

    Article  CAS  PubMed  Google Scholar 

  40. Hodgson A, Pakbaz S, Tayyari F, Young JEM, Mete O. Diagnostic pitfall: parathyroid carcinoma expands the spectrum of calcitonin and calcitonin gene-related peptide expressing neuroendocrine neoplasms. Endocr Pathol. 2019;30(2):168–72.

    Article  PubMed  Google Scholar 

  41. Szybowska M, Mete O, Weber E, Silver J, Kim RH. Neuroendocrine neoplasms associated with germline pathogenic variants in the homologous recombination pathway. Endocr Pathol. 2019;30(3):237–45.

    Article  PubMed  Google Scholar 

  42. Zabel M, Grzeszkowiak J. Characterisation of thyroid medullary carcinoma TT cell line. Histol Histopathol. 1997;12(1):283–9.

    CAS  PubMed  Google Scholar 

  43. Gucer H, Caliskan S, Kefeli M, Mete O. Do you know the details of your PAX8 antibody? Monoclonal PAX8 (MRQ-50) is not expressed in a series of 45 medullary thyroid carcinomas. Endocr Pathol. 2020;31(1):33–8.

    Article  PubMed  Google Scholar 

  44. Nelkin BD, de Bustros AC, Mabry M, Baylin SB. The molecular biology of medullary thyroid carcinoma. A model for cancer development and progression. JAMA. 1989;261:3130–5.

    Article  CAS  PubMed  Google Scholar 

  45. Mendelsohn G, Wells SA, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized and virulent disseminated stages of disease. Cancer. 1984;54:657–62.

    Article  CAS  PubMed  Google Scholar 

  46. Williams ED, Morales AM, Horn RC. Thyroid carcinoma and Cushing's syndrome. A report of two cases with a review of the common features of the non-endocrine tumours associated with Cushing's syndrome. J Clin Pathol. 1968;21:129–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Birkenhäger JC, Upton GV, Seldenrath HJ, Kreiger DT, Tashjian AH Jr. Medullary thyroid carcinoma: ectopic production of peptides with ACTH-like, corticotrophin releasing factor-like and prolactin production-stimulating activities. Acta Endocrinol (Copen). 1976;83:280–92.

    Google Scholar 

  48. Goltzman D, Huang S-N, Browne C, Solomon S. Adrenocorticotropin and calcitonin in medullary thyroid carcinoma: frequency of occurrence and localization in the same cell type by immunohistochemistry. J Clin Endocrinol Metab. 1979;49:364–9.

    Article  CAS  PubMed  Google Scholar 

  49. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Erovic BM, Kim D, Cassol C, et al. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr Pathol. 2012;23(4):232–42.

    Article  CAS  PubMed  Google Scholar 

  51. Werner TA, Tamkan-Olcek Y, Dizdar L, et al. Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma. Br J Cancer. 2016;114(4):427–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ferreira LB, Eloy C, Pestana A, et al. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. Eur J Endocrinol. 2016;174(4):551–61.

    Article  CAS  PubMed  Google Scholar 

  53. Shi W, Zhao QY, Liu ZM, Wang ST, Liu CP. Small cell carcinoma: a rare subtype of thyroid cancer with unanticipated prognosis. Curr Med Sci. 2019;39(2):265–9.

    Article  PubMed  Google Scholar 

  54. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450.

    Article  CAS  PubMed  Google Scholar 

  55. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, de Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234–45.

    Article  CAS  PubMed  Google Scholar 

  56. Makis W, McCann K, McEwan AJ. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases. Clin Nucl Med. 2015;40(5):408–12.

    Article  PubMed  Google Scholar 

  57. Beukhof CM, Brabander T, van Nederveen FH, et al. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer. 2019;19(1):325.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–9.

    Article  CAS  PubMed  Google Scholar 

  59. Tran K, Khan S, Taghizadehasl M, et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015;18(1):19–24.

    PubMed  Google Scholar 

  60. Mizukami Y, Michigishi T, Nonomura A, et al. Mixed medullary-follicular carcinoma of the thyroid occurring in familial form. Histopathology. 1993;22:284–7.

    Article  CAS  PubMed  Google Scholar 

  61. Apel RL, Alpert LC, Rizzo A, LiVolsi VA, Asa SL. A metastasizing composite carcinoma of the thyroid with distinct medullary and papillary components. Arch Pathol Lab Med. 1994;118:1143–7.

    CAS  PubMed  Google Scholar 

  62. Fink A, Tomlinson G, Freeman JL, Rosen IB, Asa SL. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol. 1996;9(8):816–20.

    CAS  PubMed  Google Scholar 

  63. Pastolero GC, Coire CI, Asa SL. Concurrent medullary and papillary carcinomas of thyroid with lymph node metastases. Am J Surg Pathol. 1996;20:245–50.

    Article  CAS  PubMed  Google Scholar 

  64. Mete O, Asa SL. Composite medullary and papillary thyroid carcinoma in a patient with MEN 2B. Case report and review of C-cell lesions of the thyroid. Pathol Case Rev. 2009;14(6):208–13.

    Article  Google Scholar 

  65. LiVolsi VA. Mixed thyroid carcinoma: a real entity? Lab Investig. 1987;57:237–9.

    CAS  PubMed  Google Scholar 

  66. Holm R, Sobrinho-Simoes M, Nesland JM, Johannessen J-V. Concurrent production of calcitonin and thyroglobulin by the same neoplastic cells. Ultrastruct Pathol. 1986;10:241–8.

    Article  CAS  PubMed  Google Scholar 

  67. Holm R, Sobrinho-Simoes M, Nesland JM, Sambade C, Johannessen J-V. Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity? Lab Investig. 1987;57:258–68.

    CAS  PubMed  Google Scholar 

  68. González-Cámpora R, Lopez-Garrido J, Martin-Lacave I, Miralles-Sánchez EJ, Villar JL. Concurrence of a symptomatic encapsulated follicular carcinoma, an occult papillary carcinoma and a medullary carcinoma in the same patient. Histopathology. 1992;21:380–2.

    Article  PubMed  Google Scholar 

  69. Baloch Z, Mete O, Asa SL. Immunohistochemical biomarkers in thyroid pathology. Endocr Pathol. 2018;29(2):91–112.

    Article  CAS  PubMed  Google Scholar 

  70. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med. 1973;289:437–41.

    Article  CAS  PubMed  Google Scholar 

  71. DeLellis RA, Wolfe HJ. The pathobiology of the human calcitonin (C)-cell: a review. Pathol Annu. 1981;16:25–52.

    CAS  Google Scholar 

  72. Asa SL, de Jesus AC, Kerr D, et al. Thyroid. In: Mete O, Asa SL, editors. Endocrine pathology. Cambridge: Cambridge University Press; 2016. p. 398–572.

    Google Scholar 

  73. Albores-Saavedra J, Monforte H, Nadji M, Morales AR. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988;19:795–9.

    Article  CAS  PubMed  Google Scholar 

  74. Biddinger PW, Brennan MF, Rosen PP. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am J Surg Pathol. 1991;15:599–604.

    Article  CAS  PubMed  Google Scholar 

  75. Scopsi L, Di Palma S, Ferrari C, Holst JJ, Rehfeld JF, Rilke F. C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Mod Pathol. 1991;4:297–304.

    CAS  PubMed  Google Scholar 

  76. Libbey NP, Nowakowski KJ, Tucci JR. C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto's thyroiditis. Am J Surg Pathol. 1989;13:71–7.

    Article  CAS  PubMed  Google Scholar 

  77. Nose V. Familial non-medullary thyroid carcinoma: an update. Endocr Pathol. 2008;19(4):226–40.

    Article  PubMed  Google Scholar 

  78. Waser B, Beetschen K, Pellegata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology. 2011;94(4):291–301.

    Article  CAS  PubMed  Google Scholar 

  79. Reagh J, Bullock M, Andrici J, et al. NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2. Am J Surg Pathol. 2017;41(1):75–81.

    Article  PubMed  Google Scholar 

  80. Sponziello M, Benvenuti S, Gentile A, et al. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. Hum Mutat. 2018;39(3):371–7.

    Article  CAS  PubMed  Google Scholar 

  81. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.

    Article  CAS  PubMed  Google Scholar 

  82. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–39.

    Article  PubMed  Google Scholar 

  83. Grubbs EG, Ng PK, Bui J, et al. RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab. 2015;100(3):788–93.

    Article  CAS  PubMed  Google Scholar 

  84. Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 1995;80:3088–90.

    CAS  PubMed  Google Scholar 

  85. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93(3):682–7.

    Article  CAS  PubMed  Google Scholar 

  86. Ji JH, Oh YL, Hong M, et al. Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer. PLoS Genet. 2015;11(8):e1005467.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Gimm O, Greco A, Hoang-Vu C, Dralle H, Pierotti MA, Eng C. Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. J Clin Endocrinol Metab. 1999;84(8):2784–7.

    CAS  PubMed  Google Scholar 

  88. Robbins RJ, Thomas JS, Osuna PM, Shakil J. A BRAF V600E mutation in RET-negative medullary thyroid cancer. Case Rep Endocrinol. 2020;2020:7641940.

    PubMed  PubMed Central  Google Scholar 

  89. Kasaian K, Wiseman SM, Walker BA, et al. Putative BRAF activating fusion in a medullary thyroid cancer. Cold Spring Harb Mol Case Stud. 2016;2(2):a000729.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Wang N, Xu D, Sofiadis A, et al. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(8):E1571–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Santarpia L, Calin GA, Adam L, et al. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer. 2013;20(6):809–23.

    Article  CAS  PubMed  Google Scholar 

  92. Meng K, Luo H, Chen H, Guo H, Xia W. Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: a population-based study using the SEER 18 database. Medicine (Baltimore). 2019;98(1):e13884.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ozgur Mete .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Asa, S.L., Mete, O. (2021). Thyroid Neuroendocrine Neoplasms. In: Asa, S.L., La Rosa, S., Mete, O. (eds) The Spectrum of Neuroendocrine Neoplasia. Springer, Cham. https://doi.org/10.1007/978-3-030-54391-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54391-4_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54390-7

  • Online ISBN: 978-3-030-54391-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics